Burkitt Lymphoma - Pipeline Review, H2 2015

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Global Markets Direct’s, ‘Burkitt Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Burkitt Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Burkitt Lymphoma Overview 7
Therapeutics Development 8
Pipeline Products for Burkitt Lymphoma - Overview 8
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 9
Burkitt Lymphoma - Therapeutics under Development by Companies 10
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 11
Burkitt Lymphoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Burkitt Lymphoma - Products under Development by Companies 14
Burkitt Lymphoma - Products under Investigation by Universities/Institutes 15
Burkitt Lymphoma - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
AmpliMed Corporation (Inactive) 17
Arvinas, Inc. 18
AstraZeneca Plc 19
Constellation Pharmaceuticals, Inc. 20
Immunomedics, Inc. 21
Karyopharm Therapeutics, Inc. 22
Millennium Pharmaceuticals, Inc. 23
Seattle Genetics, Inc. 24
Theravectys SA 25
Burkitt Lymphoma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
19-3s - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
20-3s - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alisertib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ARV-825 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AZD-6738 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
denintuzumab mafodotin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E1-3s - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ibrutinib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
imexon - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ixazomib citrate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
selinexor - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SH-7129 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SH-7133 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SH-7139 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Inhibit BET for Cancer - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vaccine for EBV Associated Cancer - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Burkitt Lymphoma - Recent Pipeline Updates 72
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Burkitt Lymphoma, H2 2015 8
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Burkitt Lymphoma - Pipeline by AbbVie Inc., H2 2015 16
Burkitt Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015 17
Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2015 18
Burkitt Lymphoma - Pipeline by AstraZeneca Plc, H2 2015 19
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 20
Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 21
Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 22
Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 23
Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 24
Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 72

List of Figures

Number of Products under Development for Burkitt Lymphoma, H2 2015 8
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Top 10 Targets, H2 2015 27
Number of Products by Stage and Top 10 Targets, H2 2015 27
Number of Products by Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Routes of Administration, H2 2015 31
Number of Products by Stage and Routes of Administration, H2 2015 31
Number of Products by Molecule Types, H2 2015 33
Number of Products by Stage and Molecule Types, H2 2015 33